Mounjaro Tirzepatide (2.5mg)

Mounjaro Weight Loss Injection (2.5mg)

Starter Dose for Safe Introduction to Dual‑Action Tirzepatide GIP/GLP‑1 Therapy

Mounjaro 2.5 mg is the official starting dose of Tirzepatide, the world’s first dual GIP + GLP‑1 receptor agonist. This introductory strength is used during the first 4 weeks of therapy to gently activate both metabolic pathways, allowing the body to adjust while minimizing gastrointestinal side effects.

As the foundation of the Mounjaro protocol, the 2.5 mg dose prepares patients for higher therapeutic strengths that deliver powerful appetite suppression, improved insulin sensitivity, and accelerated fat‑loss results.

Key Features

• Contains Tirzepatide, a dual GIP/GLP‑1 receptor agonist
• Official starter dose for Weeks 1–4
• Gently initiates appetite control
• Supports early metabolic regulation
• Minimizes GI side effects during treatment initiation
• Once‑weekly, pre‑filled injection pen
• Essential first step before therapeutic doses

How Mounjaro 2.5 mg Works

At the introductory level, Tirzepatide begins activating:

GLP‑1 Pathway

• Reduces appetite
• Slows gastric emptying
• Enhances satiety

GIP Pathway

• Improves insulin response
• Supports metabolic balance
• Prepares the body for higher doses

This phase is crucial for tolerability and long‑term success.

Indications

Mounjaro 2.5 mg is prescribed for:

• Adults with BMI ≥30
• Adults with BMI ≥27 plus a weight‑related condition
• Patients beginning Tirzepatide therapy
• Individuals requiring a safe, gradual introduction to dual‑action metabolic treatment

Benefits

• Gentle introduction to Tirzepatide
• Early appetite reduction
• Improved portion control
• Supports metabolic reset
• Convenient once‑weekly dosing
• Smooth transition to 5 mg and higher therapeutic strengths

Dosage & Titration

2.5 mg is used during Weeks 1–4 of the Mounjaro protocol:

PhaseDose**Starter2.5 mg**Step 25 mgStep 37.5 mgStep 410 mgStep 512.5 mgStep 615 mg (maximum)

This structured escalation ensures optimal tolerability and therapeutic effect.

Safety Information

Common early side effects:

• Mild nausea
• Bloating
• Fatigue
• Reduced appetite

Not suitable for:

• Pregnant or breastfeeding individuals
• Patients with personal/family history of medullary thyroid carcinoma
• Individuals with MEN2 syndrome

Mounjaro must be used under medical supervision.

Professional Use & Prescription Requirement

Mounjaro (Tirzepatide) is a prescription‑only medication and must be provided by a licensed healthcare professional